Ignite Creation Date:
2025-12-25 @ 12:04 AM
Ignite Modification Date:
2025-12-25 @ 10:02 PM
Study NCT ID:
NCT00630058
Status:
COMPLETED
Last Update Posted:
2014-05-02
First Post:
2008-02-24
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
A Phase 1 Study of MP-424, Peginterferon Alfa 2b, and Ribavirin in Hepatitis C
Sponsor:
Tanabe Pharma Corporation
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-04
Start Date Type:
None
Primary Completion Date:
2009-03
Primary Completion Date Type:
ACTUAL
Completion Date:
2009-03
Completion Date Type:
ACTUAL
First Submit Date:
2008-02-24
First Submit QC Date:
None
Study First Post Date:
2008-03-06
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2012-12-12
Results First Submit QC Date:
None
Results First Post Date:
2013-01-18
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2014-04-16
Last Update Post Date:
2014-05-02
Last Update Post Date Type:
ESTIMATED